Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines

Immunology and Cell Biology

Volumn 82, Issue 6, 2004, Pages 617-627

  Vajdy, Michael ^a   Srivastava, Indresh ^a   Polo, John ^a   Donnelly, John ^a   O'Hagan, Derek ^a   Singh, Manmohan ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adjuvant; Delivery system; Immunomodulator; Mucosal; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIGEN; CPG DNA; CTA1 DD; CYTOKINE; DNA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; ISCOM; LIPOSOME; MUCOSAL ADJUVANT; MURAMYL DIPEPTIDE; OLIGONUCLEOTIDE; PATHOGEN DERIVED ANTIGEN; PHOSPHORYL LIPID A; PLASMID DNA; POLYGLACTIN; PROTEIN; PROTEIN VACCINE; QS 21; QUIL A; RECOMBINANT PROTEIN; RNA; RNA VACCINE; SCHISTOSOMA VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIRUS VECTOR;

ALPHA VIRUS; BACTERIAL REPRODUCTION; COMPETITION; DILUTION; DISPERSION; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SELF ADMINISTRATION; DRUG TARGETING; DUST; EMULSION; ENZYMATIC DEGRADATION; EXPRESSION VECTOR; FOOD DRUG INTERACTION; IMMUNITY; IMMUNOGENICITY; IMMUNOPOTENTIATION; INFECTION; MICROENCAPSULATION; MICROPARTICLE; MUCOSA; MUCOSAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; NEEDLESTICK INJURY; NONHUMAN; PARTICULATE ANTIGEN DELIVERY SYSTEM; PH; REPLICON; REVIEW; SYSTEMIC IMMUNITY; VACCINATION; VACCINE PRODUCTION; VIRUS PARTICLE; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, MUCOSAL; NUCLEIC ACIDS; PROTEINS; VACCINES;

ADENOVIRIDAE; ALPHAVIRUS; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; POXVIRIDAE; SCHISTOSOMA;

EID: 9444242731     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2004.01288.x     Document Type: Review

References (151)

1. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001; 19: 2688-91.
2. Mora M, Veggi D, Santini L et al. Reverse vaccinology. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Drug Discov. Today 2003; 8: 459-64.
3. Rappuoli R, Pizza M, Scarlato V et al. Reverse vaccinology. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Curr. Opin. Microbiol. 2000; 3: 445-50.
4. Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287: 1816-20.
5. Clements JD, Finkelstein RA. Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect. Immun. 1979; 24: 760-69.
6. Clements JD, Yancey RJ, Finkelstein RA. Properties of homogeneous heat-labile enterotoxin from Escherichia coli. Infect. Immun. 1980; 29: 91-7.
7. Pizza M, Domenighini M, Hol W et al. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol. Microbiol. 1994; 14: 51-60.
8. Pizza M, Fontana MR, Giuliani MM et al. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J. Exp. Med. 1994; 180: 2147-53.
9. Partidos CD, Pizza M, Rappuoli R, Steward MW. The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide. Immunology 1996; 89: 483-7.
10. Giuliani MM, Del Giudice G, Giannelli V et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 1998; 187: 1123-32.
11. Singh M, Briones M, O'Hagan D. Hyaluronic acid biopolymers for mucosal delivery of vaccines. In: Abatangelo G, Weigel PH (eds) New Frontiers in Medical Sciences: Redefining hyaluronan. Amsterdam: Elsevier Science, 2000; 163-70.
12. SF2 p55 gag-specific cytotoxic responses through mucosal immunization. Immunology 2000; 101: 154-60.
13. Ugozzoli M, Santos G, Donnelly J, O'Hagan DT. Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant. J. Infect. Dis. 2001; 183: 351-4.
14. Lycke N. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Cell. Microbiol. 2004; 6: 23-32.
15. Gustafson GL, Rhodes MJ. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res. Immunol. 1992; 143: 483-8.
16. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant: Past experiences and new directions. Pharm. Biotechnol. 1995; 6: 495-524.
17. Ulrich JT. MPLr immunostimulant: adjuvant formulations. In: O'Hagan DT (ed.) Vaccine Adjuvants: Preparation Methods and Research Protocols. Totowa, NJ: Humana Press, 2000; 273-82.
18. Wheeler AW, Marshall JS, Ulrich JT. A Th1-indueing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol. 2001; 126: 135-9.
19. Childers NK, Miller KL, Tong G et al. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect. Immun. 2000; 68: 5509-516.
20. Hall MA, Stroop SD, Hu MC et al. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect. Immun. 2004; 72: 2507-512.
21. VanCott TC, Kaminski RW, Mascola JR et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J. Immunol. 1998; 160: 2000-2012.
22. Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 1991; 147: 1759-64.
23. Tokunaga T, Yamamoto H, Shimada S et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl Cancer Inst. 1984; 72: 955-62.
24. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 6546-9.
25. Bird AP. CpG islands as gene markers in the vertebrate nucleus. Trends Genet. 1987; 3: 342-7.
26. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-45.
27. Sparwasser T, Koch ES, Vabulas RM et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 1998; 28: 2045-54.
28. Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 1999; 17: 19-25.
29. Broide D, Schwarze J, Tighe H et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J. Immunol. 1998; 161: 7054-62.
30. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 2004; 199: 227-50.
31. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunization and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003; 21 (Suppl 2): S89-95.
32. Daftarian P, Ali S, Sharan R et al. Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge. J. Immunol. 2003; 171: 4028-39.
33. Dumais N, Patrick A, Moss RB, Davis HL, Rosenthal KL. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J. Infect. Dis. 2002; 186: 1098-105.
34. McCluskie MJ, Weeratna RD, Fayette PJ, Davis HL. The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit. Rev. Immunol. 2001; 21: 103-20.
35. Kensil CR. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 1996; 13: 1-55.
36. Glaueri AM, Dingle JT, Lucy JA. Action of saponins on biological membranes. Nature 1962; 196: 953.
37. Kensil CR, Kammer R. QS-21 : a water-soluble triterpene glycoside adjuvant. Exp. Opin. Invest. Drugs 1998; 7: 1475-82.
38. Boyaka PN, Marinaro M, Jackson RJ et al. Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity. J. Immunol. 2001; 166: 2283-90.
39. Sasaki S, Sumino K, Hamajima K et al. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J. Virol. 1998; 72: 4931-9.
40. Heath AW. Cytokines as immunological adjuvants. Pharm. Biotechnol. 1995; 6: 645-58.
41. Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J. Surg. Oncol. 1998; 68: 122-38.
42. Pettit DK, Lawter JR, Huang WJ et al. Characterization of poly (glycolide-co-D,1-lactide)/poly (D,1-lactide) microspheres for controlled release of GM-CSF. Pharm. Res. 1997; 14: 1422-30.
43. Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 2000; 60: 3832-7.
44. Boyaka PN, Tafaro A, Fischer R, Fujihashi K, Jirillo E, McGhee JR. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity. Curr. Pharm. Des. 2003; 9: 1965-72.
45. Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun. 2003; 71: 4780-8.
46. Bradney CP, Sempowski GD, Liao HX, Haynes BF, Staats HF. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J. Virol. 2002; 76: 517-24.
47. Staats HF, Bradney CP, Gwinn WM et al. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol. 2001; 167: 5386-94.
48. Lee S, Gierynska M, Eo SK, Kuklin N, Rouse BT. Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus. Microbes Infect. 2003; 5: 571-8.
49. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. 1995; 12: 1-99.
50. Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. (Published erratum appears in Nat Biotechnol. 1998; 16: 478.) Nat. Biotechnol. 1998; 16: 153-7.
51. Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. (Published erratum appears in Nat Biotechnol. 1998; 16: 478.) Nat. Biotechnol. 1998; 16: 153-7.
52. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly (DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immunol. 1991; 59: 2978-86.
53. O'Hagan DT, Rahman D, McGee JP et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunol. 1991; 73: 239-42.
54. O'Hagan DT, Jeffery H, Roberts MJ, McGee JP, Davis SS. Controlled release microparticles for vaccine development. Vaccine 1991; 9: 768-71.
55. O'Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993; 11: 965-9.
56. Maloy KJ, Donachie AM, O'Hagan DT, Mowat AM. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly (lactide-co-glycolide) microparticles. Immunology 1994; 81: 661-7.
57. Moore A, McGuirk P, Adams S et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 1995; 13: 1741-9.
58. Nixon DF, Hioe C, Chen PD et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996; 14: 1523-30.
59. Kanke M, Sniecinski I, DeLuca PP. Interaction of microspheres with blood constituents. I. Uptake of polystyrene spheres by monocytes and granulocytes and effect on immune responsiveness of lymphocytes. J. Parenter. Sci. Technol. 1983; 37: 210-17.
60. Tabata Y, Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of 1-lactic acid/glycolic acid homo- and copolymers. J. Biomed. Mater. Res. 1988; 22: 837-58.
61. Tabata Y, Ikada Y. Phagocytosis of polymer microspheres by macrophages. Adv. Polymer Sci. 1990; 94: 107-41.
62. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999; 11: 753-61.
63. Lutsiak ME, Robinson DR, Coester C, Kwon GS, Samuel J. Analysis of poly (D,1-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm. Res. 2002; 19: 1480-87.
64. Newman KD, Elamanchili P, Kwon GS, Samuel J. Uptake of poly (D,1-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J. Biomed. Mater. Res. 2002; 60: 480-86.
65. Kazzaz J, Neidleman J, Singh M, Ott G, O'Hagan DT. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control. Release 2000; 67: 347-56.
66. Jung T, Kamm W, Breitenbach A, Hungerer KD, Hundt E, Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft- poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm. Res. 2001; 18: 352-60.
67. Heritage PL, Brook MA, Underdown BJ, McDermott MR. Intranasal immunization with polymer-grafted microparticles activates the nasal-associated lymphoid tissue and draining lymph nodes. Immunology 1998; 93: 249-56.
68. McDermott MR, Heritage PL, Bartzoka V, Brook MA. Polymer-grafted starch microparticles for oral and nasal immunization. Immunol. Cell Biol. 1998; 76: 256-62.
69. Baras B, Benoit MA, Dupre L et al. Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen. Infect. Immun. 1999; 67: 2643-8.
70. Higaki M, Takase T, Igarashi R et al. Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin. Vaccine 1998; 16: 741-5.
71. Kim B, Bowersock T, Griebel P et al. Mucosal immune responses following oral immunization with rotavirus antigens encapsulated in alginate microspheres. J. Control. Release 2002; 85: 191-202.
72. Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Meth. 1986; 95: 157-68.
73. Lindblad EB. Freund's adjuvants. In: O'Hagan D (ed.) Vaccine Adjuvants. Preparation Method's and Research Protocols. Totowa, NJ: Humana Press, 2000; 49-64.
74. Edelman R. Adjuvants for the future. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS (eds) New Generation Vaccines. New York: Marcel Dekker, 1997; 173-92.
75. Ott G, Barchfeld GL, Chernoff D et al. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell MF, Newman MJ (eds) Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, 1995; 277-96.
76. Cataldo DM, Van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 1997; 15: 1710-15.
77. Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 1996; 14: 478-84.
78. O'Hagan DT, Ott GS, Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol. Med. Today 1997; 3: 69-75.
79. Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis. 1996; 174: 1168-75.
80. Heineman TC, Clements-Mann ML, Poland GA et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 1999; 17: 2769-78.
81. Menegon T, Baldo V, Bonello C, Dalla CD, Di Tommaso A, Trivello R. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur. J. Epidemiol. 1999; 15: 573-6.
82. De Donato S, Granoff D, Minutello M et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999; 17: 3094-101.
83. Alving CR. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim. Biophys. Acta 1992; 1113: 307-22.
84. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol. Today 1990; 11: 89-97.
85. Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15: 1209-13.
86. Barr IG, Sjolander A, Cox JC. ISCOMs and other saponin based adjuvants. Adv. Drug Del. Rev. 1998; 32: 247-71.
87. Rimmelzwaan GF, Baars M, van Seek R et al. Induction of protective immunity against influenza virus in a macaque model. Comparison Conventional Iscom Vaccines 1997; 78: 757-65.
88. Ennis FA, Cruz J, Jameson J, Klein M, Burt D, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMs). Virology 1999; 259: 256-61.
89. Soltysik S, Wu JY, Recchia J et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 1995; 13: 1403-10.
90. Lovgren-Bengtsson K, Morein B. The ISCOM™ Technology. In: O'Hagan D (ed.) Vaccine Adjuvants: Preparation Methods and Research Protocols. Totowa, NJ: Humana Press, 2000; 239-58.
91. Donnelly J, Ulmer JB, Liu MA. DNA vaccines. Life Sci. 1997; 60: 163-72.
92. Donnelly JJ, Friedman A, Martinez D et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1995; 1: 583-7.
93. Wang R, Doolan DL, Le TP et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282: 476-80.
94. Roy MJ, Wu MS, Barr LJ et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000; 19: 764-78.
95. Haas J, Park E, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 1996; 6: 315-24.
96. zur Megede J, Chen MC, Doe B et al. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J. Virol. 2000; 74: 2628-35.
97. Andre S, Seed B, Eberle J, Schraut W, Bultmann A, Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J. Virol. 1998; 72: 1497-503.
98. Uchijima M, Yoshida A, Nagata T, Koide Y. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J. Immunol. 1998; 161: 5594-9.
99. Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljestrom P. Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. 1998; 16: 562-5.
100. Hariharan MJ, Driver DA, Townsend K. et al DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J. Virol. 1998; 72: 950-58.
101. Sasaki S, Tsuki T, Asakura Y, Fukushima J, Okuda K. The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants. Anticancer Res. 1998; 18: 3907-16.
102. Ulmer JB, DeWitt CM, Chastain M et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 1999; 18: 18-28.
103. Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-8.
104. Nichols WW, Ledwith BJ, Manam SV, Troilo PJ. Potential DNA vaccine integration into host cell genome. Ann. N. Y. Acad. Sci. 1995; 772: 30-39.
105. Chattergoon MA, Robinson TM, Boyer JD, Weiner DB. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/ antigen-presenting cells. J. Immunol. 1998; 160: 5707-18.
106. Denis-Mize KS, Dupuis M, MacKichan ML et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 2000; 7: 2105-12.
107. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. 1999; 189: 169-78.
108. Bouloc A, Walker P, Grivel JC, Vogel JC, Katz SI. Immunization through dermal delivery of protein-encoding DNA: a role for migratory dendritic cells. Eur. J. Immunol. 1999; 29: 446-54.
109. Dupuis M, Murphy TJ, Higgins D et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell. Immunol. 1998; 186: 18-27.
110. Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat. Med. 1998; 4: 365-8.
111. Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl Acad. Sci. USA 2000; 97: 811-16.
112. Walter E, Moelling K, Pavlovic J, Merkle HP. Microencapsulation of DNA using poly (DL-lactide-co-glycolide): stability issues and release characteristics. 1999; 61: 361-74.
113. Ando S, Putnam D, Pack DW, Langer R. PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J. Pharm. Sci. 1999; 88: 126-30.
114. Tinsley-Bown AM, Fretwell R, Dowsett AB, Davis SL, Farrar GH. Formulation of poly (D,1-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery. J. Contro. Release 2000; 66: 229-41.
115. Briones M, Singh M, Ugozzoli M et al. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm. Res. 2001; 18: 709-11.
116. O'Hagan D, Singh M, Ugozzoli M et al. Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. J. Virol. 2001; 75: 9037-43.
117. Ott G, Singh M, Kazzaz J et al. A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. J. Control. Release 2002; 79: 1-5.
118. Van der Ven I, Sminia T. The development and structure of mouse nasal-associated lymphoid tissue: an immuno- and enzyme-histochemical study. 1993; 5: 69-75.
119. Giannasca PJ, Boden JA, Monath TP. Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins. Infect. Immun. 1997; 65: 4288-98.
120. Neutra MR, Frey A, Kraehenbuhl JP. Epithelial M cells: gateways for mucosal infection and immunization. Cell 1996; 86: 345-8.
121. Ridley Lathers DM, Gill RF, Montgomery PC. Inductive pathways leading to rat tear IgA antibody responses. Invest. Ophthalmol. Vis. Sci. 1998; 39: 1005-1011.
122. Dupuis M, Denis-Mize K, Woo C et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J. Immunol. 2000; 165: 2850-58.
123. Chattergoon MA, Kim JJ, Yang JS et al. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered fas-mediated apoptosis. Nat. Biotechnol. 2000; 18: 974-9.
124. Yan C, Rill WL, Malli R et al. Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres. Vaccine 1996; 14: 1031-8.
125. Kuper CF, Koornstra PJ, Hameleers DM et al. The role of nasopharyngeal lymphoid tissue. Immunol Today 1992; 13: 219-24.
126. Alpar HO, Almeida AJ, Brown MR. Microsphere absorption by the nasal mucosa of the rat. J. Drug Target 1994; 2: 147-9.
127. Marx PA, Compans RW, Gettie A et al. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 1993; 260: 1323-7.
128. Singh M, Ott G, Kazzaz J et al. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm. Res. 2001; 18: 1476-9.
129. Tabata Y, Ikada Y. Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. J. Pharm. Pharmacol. 1987; 39: 698-704.
130. Puri N, Sinko PJ. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation. J. Control. Release 2000; 69: 69-80.
131. Cleland JL, Barron L, Daugherty A et al. Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. J. Pharm. Sci. 1997; 85: 1350-57.
132. Singh M, Li XM, Wang H et al. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect. Immun. 1997; 65: 1716-21.
133. Singh M, Carlson JR, Briones M et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 1998; 16: 1822-7.
134. O'Hagan DT. HIV and mucosal immunity. Lancet 1991; 337: 1289.
135. O'Hagan DT, Lavelle E. Novel adjuvants and delivery systems for HIV vaccines. AIDS 2002; 16 (Suppl. 4): S115-24.
136. Cannon G, Weissman D. RNA based vaccines. DNA Cell Biol. 2002; 21; 953-61.
137. Nair S, Boczkowski D. RNA-transfected dendritic cells. Expert Rev. Vaccines 2002; 1: 507-13.
138. Khromykh AA. Replicon-based vectors of positive strand RNA viruses. Curr. Opin. Mol. Ther. 2000; 2: 555-69.
139. Polo JM, Gardner JP, Ji Y et al. Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev. Biol. 2000; 104: 181-5.
140. Schlesinger S. Alphavirus vectors: development and potential therapeutic applications. Expert Opin. Biol. Ther. 2001; 1: 177-91.
141. Leitner WW, Hwang LN, de Veer MJ et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Nat. Med. 2003; 9: 33-9.
142. Leitner WW, Hwang LN, Bergmann-Leitner ES, Finkelstein SE, Frank S, Restifo NP. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 2004; 22: 1537-44.
143. Zhou X, Berglund P, Rhodes G, Parker SE, Jondal M, Liljestrom P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 1994; 12: 1510-14.
144. Gardner JP, Frolov I, Perri S et al. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J. Virol. 2000; 74: 11 849-57.
145. Vajdy M, Gardner J, Neidleman J et al. Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles. J. Infect. Dis. 2001; 184: 1613-16.
146. Balasuriya UB, Heidner HW, Davis NL et al. Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 2002; 20: 1609-17.
147. Chen M, Hu KF, Rozell B, Orvell C, Morein B, Liljestrom P. Vaccination with recombinant alphavirus or immunestimulating complex antigen against respiratory syncytial virus. J. Immunol. 2002; 169: 3208-16.
148. Davis NL, West A, Reap E et al. Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 2002; 53: 209-11.
149. Perri S, Greer CE, Thudium K et al. An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol. 2003; 77: 10 394-403.
150. Vajdy M, Singh M, Ugozzoli M et al. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology 2003; 110: 86-94.
151. Vajdy M, Singh M, Kazzaz J et al. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intra-nasal and parenteral immunizations. AIDS Res. Hum. Retroviruses 2004; 20: in press.